Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.61 |
| ▸ | CA1 | P00915 | 7/20 | 0.61 |
| ▸ | CA4 | P22748 | 4/20 | 0.61 |
| ▸ | CA6 | P23280 | 4/20 | 0.61 |
| ▸ | CA9 | Q16790 | 5/20 | 0.45 |
| ▸ | CA7 | P43166 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | CA5A | P35218 | 3/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | PTGES2 | Q9H7Z7 | 5/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10593744 | 0.86 | CA2 (0.52) | CA2CA1CA4CA6CA9 | |
| SCHEMBL25294557 | 0.83 | CA2 (0.45) | CA2CA1CA4CA6CA9 | |
| SCHEMBL31152920 | 0.83 | CA2 (0.45) | CA2CA1CA4CA6CA9 | |
| SCHEMBL2781407 | 0.81 | CA1 (0.43) | CA2CA1CA4CA6PTGES2 | |
| SCHEMBL27883806 | 0.81 | CA1 (0.43) | CA2CA1CA4CA6PTGES2 | |
| SCHEMBL29578190 | 0.80 | PTGES2 (0.64) | CA2CA1CA4CA6CA9 | |
| SCHEMBL742940 | 0.80 | PTGES2 (0.64) | CA2CA1CA4CA6CA9 | |
| SCHEMBL3533544 | 0.80 | CA2 (0.47) | CA2CA1CA4CA6CA9 | |
| SCHEMBL25301662 | 0.78 | CA2 (0.45) | CA2CA1CA4CA6CA9 | |
| SCHEMBL28335651 | 0.78 | CA2 (0.61) | CA2CA1CA4CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109118-A1 | HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2025-04-03 | — | — | US | disclosed |
| WO-2023122938-A1 | HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023122938-A1 | HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-07-06 | — | — | WO | disclosed |
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109118-A1 | HETEROCYCLIC COMPOUNDS AS SHP2 INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | PTPN1, PTPN5, PTPN13 | CA2 883/4885CA1 1423/4885CA4 1327/4885 |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | CA2 3289/4885CA1 4506/4885CA4 4520/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | CA2 3468/4885CA1 4518/4885CA4 3900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.